FDx Advisors Inc. bought a new stake in Alkermes PLC (NASDAQ:ALKS) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 8,405 shares of the company’s stock, valued at approximately $427,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Toronto Dominion Bank lifted its position in Alkermes PLC by 12.7% in the second quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after buying an additional 212 shares during the last quarter. Greenwood Capital Associates LLC lifted its position in Alkermes PLC by 1.1% in the second quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock valued at $219,000 after buying an additional 41 shares during the last quarter. US Bancorp DE lifted its position in Alkermes PLC by 366.4% in the second quarter. US Bancorp DE now owns 3,974 shares of the company’s stock valued at $231,000 after buying an additional 3,122 shares during the last quarter. Aviance Capital Partners LLC acquired a new position in Alkermes PLC in the second quarter valued at about $232,000. Finally, Insight Capital Research & Management Inc. acquired a new position in Alkermes PLC in the second quarter valued at about $232,000. 99.02% of the stock is currently owned by institutional investors.

WARNING: “FDx Advisors Inc. Buys New Stake in Alkermes PLC (ALKS)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/20/fdx-advisors-inc-buys-new-stake-in-alkermes-plc-alks.html.

A number of research analysts have commented on the stock. BidaskClub cut shares of Alkermes PLC from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 9th. ValuEngine cut shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Barclays PLC cut shares of Alkermes PLC from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $66.00 to $50.00 in a research report on Monday, October 16th. J P Morgan Chase & Co set a $78.00 price target on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, October 27th. Finally, Jefferies Group LLC set a $69.00 price target on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, August 25th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. Alkermes PLC has an average rating of “Hold” and a consensus target price of $63.55.

In related news, SVP James M. Frates sold 20,932 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $47.58, for a total transaction of $995,944.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard F. Pops sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $48.87, for a total transaction of $2,443,500.00. The disclosure for this sale can be found here. Insiders have sold 102,498 shares of company stock worth $5,018,010 over the last 90 days. Insiders own 5.34% of the company’s stock.

Shares of Alkermes PLC (NASDAQ ALKS) opened at $48.40 on Monday. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23. Alkermes PLC has a one year low of $46.42 and a one year high of $63.40.

Alkermes PLC (NASDAQ:ALKS) last released its earnings results on Thursday, October 26th. The company reported $0.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The firm had revenue of $217.40 million for the quarter, compared to analyst estimates of $231.29 million. During the same period in the prior year, the firm earned ($0.09) earnings per share. The business’s quarterly revenue was up 20.6% compared to the same quarter last year. analysts expect that Alkermes PLC will post -0.59 earnings per share for the current year.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.